Immix Biopharma, Inc.

Name: Immix Biopharma, Inc. standardized financial statements, quarterly
Creator: Listed

IMMXNasdaqCIK 1873835HealthcareFiscal year ends Dec 31

Share this page

Link

Story card, 1080 × 1920

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Operating income−$12.5m, Q2 FY2026

Net income−$11.6m, Q2 FY2026

Immix Biopharma, Inc., income statement, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Research and development	$m	2.1	3.1	3.2	2.2	4.4	1.4	2.0	4.0	4.6	5.7	6.0	5.3
Operating income	$m	(4.5)	(5.4)	(5.6)	(4.7)	(7.4)	(5.0)	(4.7)	(6.7)	(7.7)	(10.9)	(10.8)	(12.5)
Interest expense	$m	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Income tax	$m	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	not reported	0.0
Net income	$m	(4.3)	(5.1)	(5.3)	(4.4)	(7.1)	(4.8)	(4.5)	(6.6)	(7.6)	(10.6)	(10.1)	(11.6)
Diluted EPS	$ per share	(0.23)	not reported	(0.22)	(0.15)	(0.24)	not reported	(0.15)	(0.22)	(0.24)	not reported	(0.18)	(0.18)
Basic EPS	$ per share	(0.23)	not reported	(0.22)	(0.15)	(0.24)	not reported	(0.15)	(0.22)	(0.24)	not reported	(0.18)	(0.18)

Balance sheet

Cash and equivalents$225.5m, Q2 FY2026

Shareholders' equity$228.9m, Q2 FY2026

Immix Biopharma, Inc., balance sheet, quarterly
Line item	Unit	Q3 FY20232023-09-30	FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Cash and equivalents	$m	19.6	17.5	29.3	24.0	19.7	17.7	15.9	11.6	15.9	93.9	79.3	225
Current assets	$m	22.3	19.8	32.9	27.3	22.8	20.2	16.8	12.3	16.6	101	92.3	234
Total assets	$m	22.5	19.9	34.3	28.8	25.1	22.9	19.9	15.6	20.1	105	95.8	239
Current liabilities	$m	2.8	3.7	5.7	3.9	6.6	8.7	9.3	10.0	10.9	10.1	10.5	9.3
Total liabilities	$m	2.8	3.7	6.7	4.9	7.6	9.7	10.3	11.0	11.8	11.0	11.5	10.2
Shareholders' equity	$m	19.8	16.4	27.9	23.9	17.6	13.3	9.6	4.7	8.3	93.8	84.4	229

Cash flow

Operating cash flow−$11.7m, Q2 FY2026

Capital expenditure$21.0k, Q2 FY2026

Immix Biopharma, Inc., cash flow, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Operating cash flow	$m	(3.1)	(2.7)	(3.8)	(5.3)	(4.0)	(1.5)	(1.7)	(5.3)	(5.9)	(11.0)	(9.8)	(11.7)
Capital expenditure	$m	not reported	0.0	0.3	0.1	0.3	0.5	0.1	0.1	0.4	0.2	0.0	0.0
Share repurchases	$m	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported

Diluted shares (weighted)63.77m, Q2 FY2026

Immix Biopharma, Inc., shares, quarterly
Line item	Unit	Q3 FY20222022-09-30	Q1 FY20232023-03-31	Q2 FY20232023-06-30	Q3 FY20232023-09-30	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Diluted shares (weighted)	m shares	13.9	13.9	15.0	18.6	23.4	28.8	29.4	29.7	30.0	31.9	55.4	63.8

Shares outstanding: 71.54m at Aug 3, 2026, from the cover of the 10-Q filed Aug 7, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:49 ET. Listed shows no prices and gives no investment advice.